Who Will Get First AD Drug To Market In Over A Decade?
This article was originally published in Scrip
Alzheimer's disease (AD) drug developer Axovant Sciences, which earlier this year raised a record-breaking sum of cash, has launched a large Phase III study for its 5-HT6 receptor antagonist, RVT-101– a move it hopes will set the company up to seek the first approval for any new AD product in over a decade.
You may also be interested in...
Presentation of data at Alzheimer’s Association International Conference highlights failure of Pfizer’s 5HT6 antagonist PF-05212377, while still leaving room to hope for others in class like Lundbeck’s idalopirdine and Axovant’s RVT-101
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.